Lipidosterolic Extract of Serenoa Repens Modulates the Expression of Inflammation Related-Genes in Benign Prostatic Hyperplasia Epithelial and Stromal Cells
Open Access
- 10 July 2013
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (7), 14301-14320
- https://doi.org/10.3390/ijms140714301
Abstract
Despite the high prevalence of histological Benign Prostatic Hypeplasia (BPH) in elderly men, little is known regarding the molecular mechanisms and networks underlying the development and progression of the disease. Here, we explored the effects of a phytotherapeutic agent, Lipidosterolic extract of the dwarf palm plant Serenoa repens (LSESr), on the mRNA gene expression profiles of two representative models of BPH, BPH1 cell line and primary stromal cells derived from BPH. Treatment of these cells with LSESr significantly altered gene expression patterns as assessed by comparative gene expression profiling on gene chip arrays. The expression changes were manifested three hours following in vitro administration of LSESr, suggesting a rapid action for this compound. Among the genes most consistently affected by LSESr treatment, we found numerous genes that were categorized as part of proliferative, apoptotic, and inflammatory pathways. Validation studies using quantitative real-time PCR confirmed the deregulation of genes known to exhibit key roles in these biological processes including IL1B, IL1A, CXCL6, IL1R1, PTGS2, ALOX5, GAS1, PHLDA1, IL6, IL8, NFkBIZ, NFKB1, TFRC, JUN, CDKN1B, and ERBB3. Subsequent analyses also indicated that LSESr treatment can impede the stimulatory effects of certain proinflammatory cytokines such as IL6, IL17, and IL15 in these cells. These results suggest that LSESr may be useful to treat BPH that manifest inflammation characteristics. This also supports a role for inflammation in BPH presumably by mediating the balance between apoptosis and proliferation.This publication has 48 references indexed in Scilit:
- Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasiaProceedings of the National Academy of Sciences of the United States of America, 2011
- Metallothionein and the biology of agingAgeing Research Reviews, 2011
- Biomarkers of Systemic Inflammation and Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention TrialAmerican Journal of Epidemiology, 2010
- Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysisThe Prostate, 2009
- Serum adiponectin, C‐peptide and leptin and risk of symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trialThe Prostate, 2009
- A Signaling Network in Phenylephrine-Induced Benign Prostatic HyperplasiaEndocrinology, 2009
- The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE TrialEuropean Urology, 2008
- The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophyCytokine, 2008
- Role of HIF-1 and NF-κB Transcription Factors in the Modulation of Transferrin Receptor by Inflammatory and Anti-inflammatory SignalsJournal of Biological Chemistry, 2008
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005